A total of 15,000 doses of injectable Lenacapavir (LEN) for use as a pre-exposure prophylaxis (PrEP) against HIV are expected ...

Add Yahoo as a preferred source to see more of our stories on Google. In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, ...

Share on Pinterest Research finds a new injectable form of PrEP is superior to daily oral tablets to prevent the contraction of HIV. Sara Jurado/Getty Images New research sheds light on the efficacy ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the ...

One year ago, the United States approved a new injectable drug that prevents HIV. After successful clinical trials, long-acting cabotegravir was found to be almost 100 per cent effective at preventing ...

Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and ...

According to ABC News' latest report, almost 38,000 Americans are diagnosed with HIV (human immunodeficiency virus) every year. There are already treatments to prevent HIV infection. In 2012, the Food ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden administration announced October 21. The news comes just weeks after it was announced ...

Please provide your email address to receive an email when new articles are posted on . Replacing daily oral PrEP with long-acting injectable PrEP could modestly decrease HIV incidence among men who ...

Please provide your email address to receive an email when new articles are posted on . Injectable cabotegravir administered every 8 weeks was associated with approximately nine times fewer HIV ...